Enhanced Deep Convolutional Neural Network for SARS-CoV-2 Variants Classification

Abstract

High-throughput sequencing techniques and sequence analysis have enabled the taxonomic classification of pathogens present in clinical samples. Sequencing provides an unbiased identification and systematic classification of pathogens and this is generally achieved by comparing novel sequences to pre-existing annotated reference databases. However, this approach is limited by large-scale reference databases which require considerable computational resources and skills to compare against. Alternative robust methods such as machine learning are currently employed in genome sequence analysis and classification, and it can be applied in classifying SARS-CoV-2 variants, whose continued evolution has resulted in the emergence of multiple variants.We developed a deep learning Convolutional Neural Networks-Long Short Term Memory (CNN-LSTM) model to classify dominant SARS-CoV-2 variants (omicron, delta, beta, gamma and alpha) based on gene sequences from the surface glycoprotein (spike gene). We trained and validated the model using > 26,000 SARS-CoV-2 sequences from the GISAID database. The model was evaluated using unseen 3,057 SARS-CoV-2 sequences. The model was compared to existing molecular epidemiology tool, nextclade.Our model achieved an accuracy of 98.55% on training, 99.19% on the validation and 98.41% on the test dataset. Comparing the proposed model to nextclade, the model achieved significant accuracy in classifying SARS-CoV-2 variants from unseen data. Nextclade identified the presence of recombinant strains in the evaluation data, a mechanism that the proposed model did not detect.This study provides an alternative approach to pre-existing methods employed in the classification of SARS-CoV-2 variants. Timely classification will enable effective monitoring and tracking of SARS-CoV-2 variants and inform public health policies in the control and management of the COVID-19 pandemic.

Multiple Sclerosis Stages and their Differentially Expressed Genes: A Bioinformatics Analysis

“…(2023) applied computational methods for identifying potential inhibitors targeting cdk1 in colorectal cancer, showcasing the integration of genomics and computational approaches in cancer research. In the realm of infectious diseases, Mwanga et al . (2023) developed an enhanced deep convolutional neural network for SARS-CoV-2 variants classification, highlighting the pivotal role of artificial intelligence in understanding and combating emerging viral strains.…”

Expression Level Analysis of ACE2 Receptor Gene in African-American and Non-African-American COVID-19 Patients

“…This is closely followed by Europe (9.6% of the world population) with 36.7% of cases and 28.7% of global cases and deaths respectively (2,374 deaths/million). Study reports have shown that next-generation sequences can be used to screen for disorders in newborns [9], for the study of pathogen evolution using African SARS-CoV-2 sequences [18], prostate cancer biomarker discovery [10], malaria/CoVID-19 biomarker discovery [58], SARS-CoV-2 variants classification [59], HIV-1 evolution in sub-Saharan Africa [60], analysis of RNA-seq and ChIP-seq data [61], and ebola virus comparative genomics [62]. We will be using next-generation sequencing data for our investigation in this study.…”

Differential Expression Analysis of miRNAs and mRNAs in Epilepsy Uncovers Potential Biomarkers

“…MicroRNAs have now been suggested for clinical diagnosis for a variety of disorders due to their serum stability, affordability, speed, and non-invasive qualities [15]. In the future, genomic medicine would rely largely on our ability to use sequencing data for clinical applications like biomarker discovery, viral pathogen evolution [16], SARS-CoV-2 variants classification [17], for other applications like screening for disorders in newborns [18], HIV-1 evolution in sub-Saharan Africa [78], prostate cancer biomarker discovery [79], malaria/CoVID-19 biomarker discovery [80], Chromatin Immunoprecipitation [81], and viral comparative genomics [82].…”